Cutler Group LP Reata Pharmaceuticals Inc Put Options Transaction History

Cutler Group LP

$307 Million
Q1 2024

Put Options

16 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2023 Jul 18, 2023	BUY	$79.22 - $105.37 $443,632 - $590,072	5,600 Added 86.15%	12,100 $22,000
Q1 2023 May 01, 2023	BUY	$30.85 - $93.17 $107,975 - $326,095	3,500 Added 116.67%	6,500 $8,000
Q4 2022 Feb 07, 2023	SELL	$22.15 - $42.11 $79,740 - $151,596	-3,600 Reduced 54.55%	3,000 $17,000
Q3 2022 Oct 25, 2022	BUY	$19.41 - $36.49 $93,168 - $175,152	4,800 Added 266.67%	6,600 $23,000
Q2 2022 Aug 04, 2022	SELL	$20.71 - $36.5 $946,447 - $1.67 Million	-45,700 Reduced 96.21%	1,800 $6,000
Q1 2022 Apr 14, 2022	BUY	$24.12 - $39.6 $672,948 - $1.1 Million	27,900 Added 142.35%	47,500 $72,000
Q4 2021 Jan 18, 2022	BUY	$25.61 - $110.96 $245,856 - $1.07 Million	9,600 Added 96.0%	19,600 $121,000
Q3 2021 Oct 26, 2021	BUY	$100.0 - $143.02 $880,000 - $1.26 Million	8,800 Added 733.33%	10,000 $8,000
Q2 2021 Jul 19, 2021	SELL	$78.27 - $151.29 $23,481 - $45,387	-300 Reduced 20.0%	1,200 $1,000
Q1 2021 Apr 26, 2021	BUY	$94.25 - $132.81 $75,400 - $106,248	800 Added 114.29%	1,500 $13,000
Q4 2020 Jan 21, 2021	SELL	$102.03 - $184.62 $326,496 - $590,784	-3,200 Reduced 82.05%	700 $0
Q3 2020 Oct 27, 2020	SELL	$93.53 - $163.34 $84,177 - $147,006	-900 Reduced 18.75%	3,900 $30,000
Q3 2019 Oct 28, 2019	BUY	$71.26 - $95.75 $92,638 - $124,475	1,300 Added 37.14%	4,800 $135,000
Q2 2019 Aug 09, 2019	SELL	$77.72 - $94.35 $233,160 - $283,050	-3,000 Reduced 46.15%	3,500 $105,000
Q1 2019 May 10, 2019	BUY	$51.9 - $101.79 $77,850 - $152,685	1,500 Added 30.0%	6,500 $124,000
Q3 2018 Nov 07, 2018	BUY	$35.64 - $92.06 $178,200 - $460,300	5,000 New	5,000 $6,000

Others Institutions Holding RETA

# of Institutions

Shares Held

62.7K

Call Options Held

Put Options Held

View Full List

About REATA PHARMACEUTICALS INC

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

More about RETA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.

Account